GWS
RNAM

Glassman Wealth Services’s Avidity Biosciences RNAM Stock Holding History

Glassman Wealth Services’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-32
Closed -$290 – 1470
2023
Q4 		$290 Buy
32
+6
+23% +$40 ﹤0.01% 1828
2023
Q3 		$166 Buy
+26
New +$224 ﹤0.01% 1919

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Glassman Wealth Services's RNAM Position: Q1 2024 in Review

Glassman Wealth Services sold out of Avidity Biosciences (RNAM) in Q1 2024, closing a stake of 32 shares — an estimated $290 sold.

Glassman Wealth Services first reported a position in RNAM in Q3 2023 and held it in 2 quarters. The position peaked at $290 in Q4 2023. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

  • Glassman Wealth Services reported no remaining Avidity Biosciences position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 32 Avidity Biosciences shares in Q1 2024, an estimated $290.
  • Glassman Wealth Services first reported a position in Avidity Biosciences in Q3 2023 and held it in 2 quarters.
  • Glassman Wealth Services's Avidity Biosciences position peaked at $290 in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.